Table 4:

Comparison of SNP minor allele frequency among populations for significant β₂ agonist response variants

First author, year	Gene	SNP	MAF, Black*	MAF, White**	MAF, Latino	Summary of pharmacogenomic effects noted in Table 3
Finkelstein, 200929; Wechsler 200930	ADRB2	c.46A>G, p.Arg16Gly (rs1042713)	0.51	0.63	0.57	Arg/Arg genotype associated with more pronounced response to SABA treatment in Blacks as compared with other ethnicities.29 Gly/Gly genotype associated with improvements in PEF in Blacks treated with LABA+ICS vs placebo+ICS; effect not observed in overall group and no subgroup effect for Blacks carrying Arg/Arg genotype.22
Corvol, 200912	IL6, promoter region	rs1800796 c.−572C>G	.09	.04	.27	The C allele associated with lower response to SABA among Mexicans; no effect among Puerto Ricans or Blacks.
Corvol, 200912	IL6R	c.486T>A, p.Asp162Glu (rs13306435)	.004	.009	.14	The A allele associated with reduced risk of lower drug response among Mexicans; allele frequency too low to analyze among other populations.

Note: MAF minor allele frequency; PEF peak expiratory flow; ICS inhaled corticosteroids; SABA short acting beta agonist; LABA long acting beta agonist; MAF data extracted from gnomAD browser¹¹

^*prevalence from the gnomAD African subset

^**prevalence from the European (non-Finnish) gnomAD subset.

Legend: This table provides a snapshot of the relative population prevalence of single nucleotide polymorphisms associated with variability in treatment effects (safety or effectiveness) among Blacks as compared with other groups.